Adding Carvedilol Therapy Prevents Progression of Chronic Kidney Disease: Presented at ASN
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Adding Carvedilol Therapy Prevents Progression of Chronic Kidney Disease: Presented at ASN

By Bryan DeBusk, PhD

SAN FRANCISCO, CA -- November 6, 2007 -- Patients with stage 3 chronic kidney disease (CKD) who receive carvedilol in addition to their other prescribed therapies are 29.8% less likely to progress to stage 4 CKD over a 3-year period.

Naoyuki Nakao, MD, Clinician, Division of Nephrology and Dialysis, Kohnan Hospital, Kobe, Japan, reported the findings here at Renal Week 2007, the American Society of Nephrology (ASN) Annual Meeting.

Dr. Nakao and colleagues randomised 245 patients with stage 3 or stage 4 CKD into two groups to receive placebo (n = 122) or 3.75 to 30 mg carvedilol (n = 123) three times a day.

Patients were followed for 3 years to examine time of doubling of serum creatinine and time to progression of end-stage renal disease (ESRD).

Following adjustments for baseline blood pressure, rate of daily urinary protein production, renal function, and diabetes, patients receiving carvedilol had a 0.70 relative risk for doubling serum creatinine and progressing to ERSD (95% confidence interval [CI], 0.56-0.80, P =.009).

An additional reduction in heart rate was observed in the group receiving carvedilol (P =.01), but no difference was noted in blood pressure between the two groups.

Dr. Nakao also noted that carvedilol significantly reduced the number of cardiovascular disease events despite the underlying CKD stage.

Although the effects on progression to more severe CKD were primarily limited to individuals with stage 3 CKD, Dr. Nakao concluded that "carvedilol should be considered another tool for better management of those at high risk."

[Presentation Title: A Randomized Trial of the B-Adrenergic Antagonist Carvediol in Chronic Kidney Disease (CCARE Trial). Abstract SA-FC039]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities